Advanced search
Publication Cover
OncoTargets and Therapy Volume 11, 2018 - Issue
Submit an article Journal homepage
47
Views
7
CrossRef citations to date
0
Altmetric
Case Report

Role of chemotherapy with epidermal growth factor receptor-tyrosine kinase inhibitor (EGFR-TKI) rechallenge in small cell transformation after EGFR-TKI failure: a case report

Sanghun Lee1 Department of Medical Consilience, Graduate School, Dankook University, Yongin, Republic of Korea
,
Jeonghyun Joo2 Department of Korean Internal Medicine, Comprehensive and Integrative Medicine Hospital, Daegu, Republic of Korea
,
Minah Kwak3 Department of Internal Medicine, College of Korean Medicine, Daegu Haany University, Daegu, Republic of Korea
,
Kicheul Sohn4 Department of Preventive Medicine, Daegu Catholic University Medical Center, Daegu, Republic of Korea
&
Songha Chon5 Department of Hemato-Oncology, Comprehensive and Integrative Medicine Hospital, Daegu, Republic of Korea, [email protected]Correspondence[email protected]
Pages 3943-3947 | Published online: 09 Jul 2018

References

  • SiegelRLMillerKDJemalACancer statistics, 2016CA Cancer J Clin201666173026742998
  • LiCGFangRSunYHSpectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokersPLoS One2011611e2820422140546
  • JackmanDPaoWRielyGJClinical definition of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small-cell lung cancerJ Clin Oncol201028235736019949011
  • KobayashiSBoggonTJDayaramTEGFR mutation and resistance of non-small-cell lung cancer to gefitinibN Engl J Med2005352878679215728811
  • BeanJBrennanCShihJYMET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinibProc Natl Acad Sci U S A200710452209322093718093943
  • TakezawaKPirazzoliVArcilaMEHER2 amplification: a potential mechanism of acquired resistance to EGFR inhibition in EGFR-mutant lung cancers that lack the second-site EGFRT790M mutationCancer Discov201221092293322956644
  • SequistLVWaltmanBADias-SantagataDGenotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitorsSci Transl Med201137575ra26
  • BeckerACrombagLHeidemanDARetreatment with erlotinib: regain of TKI sensitivity following a drug holiday for patients with NSCLC who initially responded to EGFR-TKI treatmentEur J Cancer201147172603260621784628
  • CappuzzoFMorabitoANormannoNEfficacy and safety of rechallenge treatment with gefitinib in patients with advanced non-small cell lung cancerLung Cancer201699313727565910
  • NSCLC Meta-Analyses Collaborative GroupChemotherapy in addition to supportive care improves survival in advanced non-small-cell lung cancer: a systematic review and meta-analysis of individual patient data from 16 randomized controlled trialsJ Clin Oncol200826284617462518678835
  • MurrayNTurrisiATA review of first-line treatment for small-cell lung cancerJ Thorac Oncol20061327027817409868
  • OserMGNiederstMJSequistLVEngelmanJATransformation from non-small-cell lung cancer to small-cell lung cancer: molecular drivers and cells of originLancet Oncol2015164e165e17225846096
  • JiangSYZhaoJWangMZSmall-cell lung cancer transformation in patients with pulmonary adenocarcinoma: a case report and review of literatureMedicine2016956e275226871823
  • NishimuraJMiyamotoYFujimotoNAdenocarcinoma of the lung acquiring resistance to afatinib by transformation to small cell carcinoma: a case reportCase Rep Oncol201710266667028878647

Related research

People also read lists articles that other readers of this article have read.

Recommended articles lists articles that we recommend and is powered by our AI driven recommendation engine.

Cited by lists all citing articles based on Crossref citations.
Articles with the Crossref icon will open in a new tab.